An update from AstraZeneca ( (GB:AZN) ) is now available.
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved by the European Union as the first HER2-directed therapy for patients with HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer following endocrine therapy. This approval, based on the DESTINY-Breast06 Phase III trial results, positions Enhertu as a superior alternative to chemotherapy, offering a median progression-free survival of over a year. The approval expands the eligible patient population and marks a significant advancement in breast cancer treatment, potentially impacting AstraZeneca’s market positioning and providing new treatment options for patients.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, cardiovascular, renal, and metabolism, and respiratory areas. The company collaborates with Daiichi Sankyo to develop Enhertu, a HER2-directed antibody drug conjugate.
YTD Price Performance: 8.82%
Average Trading Volume: 2,714,787
Technical Sentiment Signal: Strong Sell
Current Market Cap: £176.2B
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.